BioTuesdays

Tag - Cantor Fitzgerald

Disc-Medicine-Logo
Markets

Cantor starts Disc Medicine at OW; PT $45

Cantor Fitzgerald launched coverage of Disc Medicine (NASDAQ:IRON) with an “overweight” rating and 12-month price target of $45. The stock closed at $32.24 on April 27. Disc Medicine is a clinical-stage...

April 28, 2023
Transgene-Logo
Markets

Cantor starts Transgene at OW; PT €4

Cantor Fitzgerald launch coverage of France-based Transgene (TNG:PA) with an “overweight” rating and a 12-month price target of €4. The stock was quoted at €2.01 on Feb. 17. “Our constructive view on Transgene stock is...

February 17, 2023
MoonLake Logo
Markets

Cantor starts MoonLake at OW; PT $23

Cantor Fitzgerald initiated coverage of MoonLake Immunotherapeutics (NASDAQ:MLTX) with an “overweight” rating and a 12-month price target of $23. The stock closed at $16.30 on Feb. 13. MoonLake has an IL-17A and IL-17F...

February 14, 2023
Outlook Therapeutics Logo
Markets

Cantor starts Outlook Therapeutics at OW; PT $4

Cantor Fitzgerald launched coverage of Outlook Therapeutics (NASDAQ:OTLK) with an “overweight” rating and a 12-month price target of $4. The stock closed at $1.15 on Feb. 3. Outlook is a biopharmaceutical company that...

February 6, 2023
Editas-Logo
Markets

Cantor starts Editas Medicine at OW; PT $15

Cantor Fitzgerald initiated coverage of Editas Medicine (NASDAQ:EDIT) with an “overweight” rating and 12-month price target of $15. The stock closed at $9.35 on Jan. 31. Editas is a clinical-stage gene editing company...

February 1, 2023
Precigen-Logo
Markets

Cantor ups Precigen PT after R&D event

Cantor Fitzgerald raised its price target for Precigen (NASDAQ:PGEN) to $10 from $7 after the company held an R&D event to showcase safety and efficacy data from a Phase 1 trial. The stock closed at $1.64 on Jan. 27...

January 30, 2023
Ardelyx Logo
Markets

Cantor ups Ardelyx PT to $3 after FDA update

Cantor Fitzgerald raised its price target for Ardelyx (NASDAQ:ARDX) to $3 from $1.60 but maintained a “neutral” rating after a label update from the FDA. The stock closed at $2.51 on Dec. 28. Ardelyx announced that the...

December 29, 2022
X4 Pharma
Markets

Cantor starts X4 Pharma at OW; PT $3

Cantor Fitzgerald launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with an “overweight” rating and a 12-month price target of $3. The stock closed at 80 cents on Dec. 22. X4 is a clinical-stage biopharmaceutical...

December 22, 2022
Provention Bio Logo
Markets

Cantor ups Provention Bio PT on FDA T1D approval

Cantor Fitzgerald raised its price target for Provention Bio (NASDAQ:PRVB) to $16 from $12 and maintained an “overweight” rating after the FDA approved teplizumab (brand name, TZIELD) to delay the onset of Type 1...

November 18, 2022